Reported 5 months ago
The article discusses why Bristol Myers Squibb (BMY) may be a good investment despite its recent struggles. The pharmaceutical company has a high dividend yield of 5.6% and a reasonable payout ratio, but has faced challenges with slower-than-expected drug launches and upcoming patent cliffs. However, BMY has a history of successful acquisitions and has recently acquired Karuna Therapeutics, which could be a potential blockbuster. The article suggests that BMY's long-term value creation potential may make it an attractive investment for contrarian investors looking for a high-yield dividend stock with growth potential.
Source: YAHOO